PL1
Sponsors
Actelion Pharmaceuticals Ltd., Janssen - Cilag International, Biogen Idec Research Limited, Inventiva, Centre Hospitalier Universitaire De Bordeaux
Conditions
Agitation with Dementia of the Alzheimer's TypeAmyotrophic Lateral Sclerosis (ALS) associated with SOD1 gene mutationAneurysms-osteoarthritis syndromeArterial Tortuosity syndromeDepressive-anxiety states in people with heart failure with preserved ejection fractionDuchenne muscular dystrophy; Cardiomyopathy; TachycardiaEarly Alzheimer's DiseaseFamilial thoracic aortic aneurysms and aortic dissections
Phase 1
Phase 2
Effect of Tafoxiparin on Cervical Ripening and Induction of Labor in Term Pregnant Women With an Unripe Cervix
CompletedNCT04000438
Start: 2019-06-21End: 2023-03-30Updated: 2025-05-06
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study with a Long-Term Extension Treatment Period to Assess the Efficacy and Safety of JNJ-63733657, an Anti-tau Monoclonal Antibody, in Participants with Early Alzheimer's Disease
Active, not recruitingCTIS2022-501188-42-00
Start: 2021-04-15Target: 195Updated: 2025-12-16
Phase II/III double-blind randomized placebo-controlled trial assessing the preventive effect of Clopidogrel on the systemic sclerosis development risk in subjects with specific dysimmunity and Raynaud phenomenon - PSSIT
RecruitingCTIS2024-511005-39-00
Start: 2022-06-22Target: 90Updated: 2025-07-11
Randomized placebo-controlled trial comparing Methotrexate vs. Methotrexate/Metformin association in rheumatoid arthritis patients: METorMET² study.
Active, not recruitingCTIS2024-511033-35-00
Start: 2020-12-03Target: 128Updated: 2024-07-09
Phase 3
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group Study with Open-Label Extension Period to Assess the Efficacy and Safety of Selexipag as Add-On Treatment to Standard of Care in Children Aged ≥2 to <18 years with Pulmonary Arterial Hypertension
Active, not recruitingCTIS2022-501012-34-00
Start: 2020-02-27Target: 73Updated: 2025-11-03
A Phase 3 Study of the Efficacy, Safety, and Pharmacokinetics of Ustekinumab as Open-label Intravenous Induction Treatment Followed by Randomized Double-blind Subcutaneous Ustekinumab Maintenance in Pediatric Participants with Moderately to Severely Active Crohn’s Disease
CompletedCTIS2023-504978-38-00
Start: 2021-03-16End: 2025-03-03Target: 60Updated: 2024-09-24
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Masupirdine (SUVN-502) for the Treatment of Agitation in Participants with Dementia of the Alzheimer's Type
RecruitingCTIS2024-513835-25-00
Start: 2022-10-27Target: 157Updated: 2025-07-04
A Phase 3 Randomized, Placebo-Controlled Trial With a Longitudinal Natural History Run-In and Open-Label Extension to Evaluate BIIB067 Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation (ATLAS)
Active, not recruitingCTIS2023-505641-12-00
Start: 2021-07-27Target: 30Updated: 2025-08-28
A randomised, double-blind, placebo-controlled, multicentre, Phase 3 study evaluating efficacy and safety of lanifibranor followed by an active treatment extension in adult patient with non-cirrhotic non-alcoholic steatohepatitis (NASH) and fibrosis 2 (F2)/fibrosis 3 (F3) stage of liver fibrosis
Active, not recruitingCTIS2023-508248-23-00
Start: 2021-11-26Target: 236Updated: 2025-11-10
Evaluation of the Efficacy of Valsartan in Slowing Down Aortic Root Dilatation in Children and Young Adults with Marfan-type Heritable Thoracic Aortic Diseases – Valsar-TAD, a randomised, double-blind, placebo-controlled multicentre trial
RecruitingCTIS2024-515059-39-00
Start: 2024-02-09Target: 180Updated: 2025-06-30
The effect of sertraline on anxiety-depressive symptoms, endothelial dysfunction and biomarkers in heart failure patients with preserved ejection fraction
CompletedCTIS2024-515061-33-00
Start: 2024-03-22End: 2025-12-05Target: 485Updated: 2025-07-24
The efficacy and safety of Metoprolol as add-on treatment to standard of care in preventing cardiomyopathy in patients with Duchenne Muscular Dystrophy aged 8-17 years. A randomized, double-blind, placebo controlled study
CompletedCTIS2024-515057-19-00
Start: 2021-07-12End: 2025-10-06Target: 144Updated: 2024-12-16